Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2 breast cancer (BC): Biomarker analysis of the APHINITY trial.
Ian E Krop, Joseph Paulson, Christine Campbell, Astrid Christina Kiermaier, Fabrice Andre, Debora Fumagalli, Sanne de Haas, Roberto Salgado, Carsten Denkert, Sibylle Loibl, Andrew Bailey, Gail Lewis Phillips, Elizabeth Frank, Martine Piccart, Giuseppe Viale, Sherene Loi
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019
1012 Background: We conducted a comprehensive genomic and immune-marker based analysis to identify prognostic and predictive biomarkers beyond clinical parameters (eg nodal status) in the setting of HP-based therapy. Methods: APHINITY, a phase III study, randomized 4805 pt with HER2+ BC to adjuvant chemo/H, plus P or placebo. Tumor Infiltrating Lymphocytes (TILs) were analysed using published methods. A nested case-control design with 1023 pt samples (3 controls matched to 1 distant relapse) underwent DNA (targeted) and RNA sequencing. Inverse probability weighting with Kaplan-Meier estimator weights, and models adjusted for treatment, hormone receptor, nodal status, age and chemotherapy ty..View full abstract